

## News Release

Your Contact

**Media Relations**

thomas.moeller@emdgroup.com

Phone: +49 151 1454-2005

**Investor Relations**

investor.relations@emdgroup.com

Phone: +49 6151 72-3321

July 2020

## Changes in Merck KGaA, Darmstadt, Germany, Executive Board

- **Belén Garijo appointed Vice Chairman of the Executive Board and Deputy CEO**
- **Udit Batra leaves the company to pursue other opportunities outside Merck KGaA, Darmstadt, Germany**
- **Christos Ross will lead Life Science business sector on interim basis**
- **Marcus Kuhnert takes over additional Executive Board responsibility for Information Technology**

Darmstadt, Germany, July 13, 2020 – The Board of Partners of E. Merck KG, Darmstadt, Germany, appointed Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO of Merck KGaA, Darmstadt, Germany, effective today. She will maintain her current Executive Board responsibilities.

“The appointment of Belén Garijo as Vice Chairman of the Executive Board and Deputy CEO recognizes her outstanding achievements for our Healthcare business and her strong leadership in the critical corporate functions Human Resources and Environment, Health, Safety, Security, Quality”, said Johannes Baillou, Chairman of the Board of Partners of E. Merck KG, Darmstadt, Germany.

Udit Batra has decided to pursue other opportunities outside Merck KGaA, Darmstadt, Germany. Effective today, the contract of Mr. Batra as General Partner



## News Release

of E. Merck KG Darmstadt, Germany, and Executive Board Member of Merck KGaA, Darmstadt, Germany, has been resolved.

“We would like to thank Udit Batra for nine years of service to our company, his great accomplishments and strong commitment towards science and technology. Together with his team, he ensured a successful integration of Sigma-Aldrich and continuously developed our global life science business. We wish him every success and all the very best for the future”, said Johannes Baillou.

The Board of Partners of E. Merck KG, Darmstadt, Germany, will decide about a successor in due course. On an interim basis, Christos Ross will take over the Life Science business lead, reporting to Stefan Oschmann, Chairman of the Executive Board and CEO. Ross joined Merck KGaA, Darmstadt, Germany, in 2008 and currently serves as Executive Vice President Integrated Supply Chain Operations within the Life Science business sector.

Belén Garijo joined Merck KGaA, Darmstadt, Germany, in 2011 as Chief Operating Officer of the Biopharma business and was appointed to the Executive Board in 2015. She is CEO of the Healthcare business and in charge of the corporate functions Human Resources and Environment, Health, Safety, Security, Quality.

Udit Batra joined Merck KGaA, Darmstadt, Germany, in 2011, took over responsibility for the Life Science business sector in 2014 and was appointed to the Executive Board in 2016. In 2017, he also assumed responsibility for Information Technology.

Marcus Kuhnert, Member of the Executive Board, Chief Financial Officer and in charge of Merck KGaA, Darmstadt, Germany, Business Services and Procurement, will in addition take over the Executive Board responsibility for Information Technology.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to [www.emdgroup.com/subscribe](http://www.emdgroup.com/subscribe) to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

## News Release

### **About Merck KGaA, Darmstadt, Germany**

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.